Scott Edil Pharmacia Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Scott Edil Pharmacia Limited Pharmaceutical Export Portfolio Dataset — 23 Products, $25.5M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Scott Edil Pharmacia Limited — Pharmaceutical Exporter Profile (2026) | 23 Products, $25.5M Trade | TransData Nexus

Scott Edil Pharmacia Limited

Indian Pharmaceutical Exporter · Antibiotics Specialist · $25.5M Total Trade · DGFT Verified

Scott Edil Pharmacia Limited is an Indian pharmaceutical exporter with a total trade value of $25.5M across 23 products in 10 therapeutic categories. Based on 1,018 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ceftriaxone ($5.7M), Artesunate ($3.2M), Azithromycin ($2.7M).

Scott Edil Pharmacia Limited — Export Portfolio & Destination Treemap

Scott Edil Pharmacia Limited pharmaceutical export portfolio — 23 products across 10 therapeutic categories. Source: Indian Customs (DGFT).

Who is Scott Edil Pharmacia Limited? — Company Overview & Market Position

Scott-Edil Pharmacia Limited, established in 1996, is a prominent Indian pharmaceutical company committed to providing equitable and affordable healthcare. Incorporated as a public limited company on January 6, 2003, under the Corporate Identification Number (CIN) U24232CH2003PLC025699, the company is headquartered at Plot No. 28/6, Industrial Area, Phase-2, Chandigarh, India. The authorized share capital stands at ₹130 million, with a paid-up capital of ₹127.68 million. Scott-Edil Pharmacia Limited operates as a non-government company, focusing on the manufacturing of pharmaceuticals, medicinal chemicals, and botanical products. The company employs approximately 1,500 professionals across its operations. For more information, visit their official website at https://scott-edil.com/.

What Does Scott Edil Pharmacia Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ceftriaxone$5.7M 2Artesunate$3.2M

Product Portfolio — Top 23 by Export Value

Scott Edil Pharmacia Limited exports 23 pharmaceutical products across 10 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ceftriaxone	Advanced Antibiotics	$5.7M	218	2.0%	11
2	Artesunate	Antimalarial & Antiparasitic	$3.2M	74	1.9%	6
3	Azithromycin	Antibiotics	$2.7M	68	1.5%	14
4	Ampicillin	Antibiotics	$2.3M	61	1.6%	10
5	Cephalexin	Antibiotics	$2.2M	53	0.6%	12
6	Heparin	Cardiovascular	$1.7M	53	0.5%	14
7	Vancomycin	Antibiotics	$1.2M	28	1.3%	12
8	Albendazole	Antimalarial & Antiparasitic	$958.2K	78	1.3%	15
9	Amikacin	Advanced Antibiotics	$875.1K	108	4.1%	7
10	Gentamicin	Antibiotics	$869.6K	53	1.7%	11
11	Ketorolac	Analgesics & Antipyretics	$576.3K	32	0.5%	13
12	Quinine	Antimalarial & Antiparasitic	$548.3K	11	2.8%	7
13	Dextromethorphan	Respiratory & OTC	$484.1K	26	3.3%	7
14	Lisinopril	Cardiovascular	$380.4K	21	0.6%	14
15	Metoclopramide	Gastrointestinal	$343.9K	44	1.5%	7
16	Flucloxacillin	Advanced Antibiotics	$320.4K	22	0.8%	13
17	Tinidazole	Advanced Antibiotics	$263.8K	16	1.4%	14
18	Empagliflozin	Diabetes & Endocrine	$260.7K	12	3.9%	5
19	Indomethacin	Analgesics & Antipyretics	$154.1K	10	1.6%	9
20	Disprin	Brand Names & OTC Products	$124.9K	3	1.2%	3
21	Aminophylline	Respiratory & OTC	$106.3K	18	1.8%	7
22	Terbutaline	Respiratory & OTC	$83.6K	5	2.4%	6
23	Paracetamol Caffeine	Combination Drugs	$40.1K	4	2.9%	7

Scott Edil Pharmacia Limited exports 23 pharmaceutical products across 10 therapeutic categories with a total export value of $25.5M. The top category is Antibiotics (36.6% of portfolio), followed by Advanced Antibiotics (28.1%), indicating a concentrated portfolio with the top 5 products accounting for 63.4% of total export value.

Scott Edil Pharmacia Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Scott-Edil Pharmacia Limited operates four state-of-the-art manufacturing plants, all compliant with WHO-GMP standards. Three of these facilities are located in Baddi, Himachal Pradesh, and one in Chandigarh, India. These plants are equipped with ultra-modern machinery and quality control laboratories, ensuring adherence to stringent quality standards. The manufacturing capabilities include injections (both dry and liquid forms), ophthalmic solutions, oral liquids, dry syrups, tablets, capsules, gels, hand sanitizers, dietary proteins, and food supplements.

3Key Leadership

The leadership team at Scott-Edil Pharmacia Limited comprises several key executives:

Vaishali Aggarwal: Managing Director
Sanjeev Kumar: Director
Balram Krishan: Director
Munish Kumar: Director
Pushkin Sharma: Director
Vipan Kumar: Director

These individuals play pivotal roles in steering the company's strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Scott Edil Pharmacia Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Scott-Edil Pharmacia Limited has established a significant presence in various regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has undertaken efforts to obtain EU GMP certification for its facilities, aiming to enhance its market access in the European Union. While specific details regarding regulatory filings, approvals, and market access status in the United States, United Kingdom, Australia, and Japan are not publicly disclosed, the company's commitment to international quality standards suggests a proactive approach to compliance in these markets.

2Emerging Markets

Scott-Edil Pharmacia Limited has expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's products are exported to countries such as Russia, Ukraine, Georgia, Iraq, Afghanistan, Kazakhstan, Philippines, Vietnam, Yemen, South Sudan, Nigeria, Zimbabwe, and Sri Lanka. The pursuit of WHO prequalification for its facilities is a strategic move to facilitate access to these markets, as WHO prequalification is often a prerequisite for supplying medicines to various international organizations and countries.

3Geographic Strategy

Scott Edil Pharmacia Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Scott-Edil Pharmacia Limited's FDA facility registrations, approved ANDAs, DMF filings, and inspection history are not publicly available. The company's commitment to WHO-GMP standards and its pursuit of EU GMP certification suggest a focus on adhering to international quality standards, which may facilitate future interactions with regulatory bodies such as the FDA.

2WHO & EU GMP

Scott-Edil Pharmacia Limited's manufacturing facilities are WHO-GMP certified, indicating compliance with the World Health Organization's Good Manufacturing Practices. The company is also in the process of obtaining EU GMP certification, aiming to meet the European Union's stringent manufacturing standards.

3CDSCO & Indian Regulatory

Scott-Edil Pharmacia Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company also possesses approvals from state drug controllers and export No Objection Certificates (NOCs), facilitating its export activities.

Scott Edil Pharmacia Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Scott-Edil Pharmacia Limited operates in a competitive landscape with several key players in the pharmaceutical manufacturing sector. While specific market share comparisons are not publicly disclosed, the company's extensive product portfolio, commitment to quality standards, and global export reach position it as a significant competitor in the industry.

2Key Differentiators

Scott-Edil Pharmacia Limited's key differentiators include its extensive product portfolio of over 700 drug formulations across various therapeutic segments, adherence to international quality standards such as WHO-GMP and ISO 9001:2008 certifications, and a strong presence in both domestic and international markets.

3Strategic Position

Scott-Edil Pharmacia Limited's current strategic direction focuses on expanding its global footprint through exports, enhancing product offerings across multiple therapeutic categories, and obtaining international certifications to facilitate market access. The company's future outlook includes further diversification of its product portfolio and strengthening its position in emerging markets.

Buyer Due Diligence Brief — Evaluating Scott Edil Pharmacia Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Scott-Edil Pharmacia Limited has a track record of consistent export volumes, with a total export value of $25.5 million USD and 1,018 shipments across 23 products in 10 therapeutic categories. The company's adherence to international quality standards and its proactive approach to obtaining certifications such as EU GMP and WHO prequalification indicate a reliable and consistent supplier.

2Certifications to Verify

Importers should verify the following certifications when considering products from Scott-Edil Pharmacia Limited:

WHO-GMP Certification: Indicates compliance with the World Health Organization's Good Manufacturing Practices. Verification can be done through the WHO's official website or by contacting the company directly.

EU GMP Certification: Demonstrates adherence to the European Union's Good Manufacturing Practices. Verification can be conducted through the European Medicines Agency (EMA) or by reaching out to the company.

Frequently Asked Questions — Scott Edil Pharmacia Limited

How many pharmaceutical products does Scott Edil Pharmacia Limited export from India?

Scott Edil Pharmacia Limited exports 23 pharmaceutical products across 10 therapeutic categories. The top exports are Ceftriaxone ($5.7M), Artesunate ($3.2M), Azithromycin ($2.7M), Ampicillin ($2.3M), Cephalexin ($2.2M). Total export value is $25.5M.

What is Scott Edil Pharmacia Limited's total pharmaceutical export value?

Scott Edil Pharmacia Limited's total pharmaceutical export value is $25.5M, based on 1,018 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Scott Edil Pharmacia Limited cover?

Scott Edil Pharmacia Limited exports across 10 therapeutic categories. The largest are Antibiotics (36.6%, 5 products), Advanced Antibiotics (28.1%, 4 products), Antimalarial & Antiparasitic (18.4%, 3 products).

Get Full Scott Edil Pharmacia Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.